<DOC>
	<DOC>NCT00612703</DOC>
	<brief_summary>To determine the safety, tolerability and recommended Phase 2 dose of ARQ 197 when administered in combination with erlotinib to patients with advanced solid tumors</brief_summary>
	<brief_title>A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Signed written informed consent must be obtained and documented according to International Conference on Harmonization (ICH) Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior to studyspecific screening procedures A histologically or cytologically confirmed solid tumor that is advanced, metastatic, and/or inoperable following prior standard chemotherapy, and/or for which, in the opinion of the investigator, there is no alternative therapy, or for which monotherapy with erlotinib is appropriate ≥ 18 years of age Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Anticancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of first dose (patients currently on erlotinib monotherapy may be enrolled into the study without a washout) Major surgery within 4 weeks prior to first dose Central nervous system metastasis unless it has been stable for ≥ 3 months after treatment and patient has no neural symptoms Pregnant or breastfeeding Significant gastrointestinal disorder that, in the opinion of the Investigator, could interfere with the absorption of ARQ 197 and/or erlotinib (e.g. significant, uncontrolled inflammatory bowel disease or extensive small bowel resection)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Cancer, oral, erlotinib, tarceva, solid tumor, advanced tumor, phase 1</keyword>
	<keyword>Tumor</keyword>
</DOC>